Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent
Summary Background Data comparing tofacitinib and vedolizumab in ulcerative colitis (UC) are lacking. Aims To compare the effectiveness of tofacitinib and vedolizumab in patients with UC who had prior exposure to anti‐TNF therapy Methods In this multicentre study, we included consecutive patients wi...
Gespeichert in:
| Veröffentlicht in: | Alimentary Pharmacology & Therapeutics (Suppl) 2023-03, Vol.57 (6), p.676-688 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 688 |
|---|---|
| container_issue | 6 |
| container_start_page | 676 |
| container_title | Alimentary Pharmacology & Therapeutics (Suppl) |
| container_volume | 57 |
| creator | Buisson, Anthony Nachury, Maria Guilmoteau, Thomas Altwegg, Romain Treton, Xavier Fumery, Mathurin Serrero, Melanie Leclerc, Eloïse Caillo, Ludovic Pereira, Bruno Amiot, Aurélien Bouguen, Guillaume |
| description | Summary
Background
Data comparing tofacitinib and vedolizumab in ulcerative colitis (UC) are lacking.
Aims
To compare the effectiveness of tofacitinib and vedolizumab in patients with UC who had prior exposure to anti‐TNF therapy
Methods
In this multicentre study, we included consecutive patients with UC ≥18 years old with partial Mayo score >2 and prior anti‐TNF exposure, who started tofacitinib or vedolizumab between January 2019 and June 2021. Comparisons were performed using propensity score analyses (inverse probability of treatment weighting).
Results
Overall, 126 and 178 patients received tofacitinib and vedolizumab, respectively. Intensified induction (vedolizumab infusion at week 10 or tofacitinib 10 mg b.d until week 16) was performed in 28.5% and 41.5% of patients, respectively.
After propensity‐score analysis, corticosteroid‐free clinical remission (partial Mayo score ≤2) was achieved at week 16 in 45.1% and 40.2% of patients receiving tofacitinib and vedolizumab, respectively (aOR = 0.82 [0.35–1.91], p = 0.64). Endoscopic improvement (corticosteroid‐free clinical remission and endoscopic Mayo score ≤1) (aOR = 0.23[0.08–0.65], p = 0.0032) and histological healing (endoscopic improvement + Nancy histological index ≤1) (13.4% vs 3.2%, aOR = 0.21[0.05–0.91], p = 0.023) were higher at week 16 in patients treated with tofacitinib. No factor was predictive of tofacitinib effectiveness. At least one primary failure to a biologic (OR = 0.46[0.22–0.99], p = 0.049), partial Mayo score >6 (OR = 0.39[0.17–0.90], p = 0.029) and CRP level > 30 mg/L at baseline (OR = 0.08[0.01–0.85], p = 0.036) were associated with vedolizumab failure.
Conclusion
Tofacitinib and vedolizumab are effective in UC after failure of anti‐TNF agents. However, tofacitinib seems more effective, especially in severe disease and primary failure to biologics.
Graphical showing the comparison between tofacitinib and vedolizumab to achieve steroid‐free clinical remission, endoscopic improvement and histological healing at week 16 in patients with ulcerative colitis exposed to at least one anti‐TNF agent |
| doi_str_mv | 10.1111/apt.17305 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03870253v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2738192426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3875-1f82b5b65a6664501a248b135e638c5108b54856ad696ba66db514392c982eb63</originalsourceid><addsrcrecordid>eNp1kc9u1DAQhy0EokvhwAsgS1zgkNZ_Yq9zXFW0RVoBQsvZspMJdeXYIXZ2Kac-AldejyfBy5YiIeHLSNY338zoh9BzSk5oeadmzCd0yYl4gBaUS1ExwuVDtCBMNhVTlB-hJyldE0LkkrDH6IjLmlChxAL9-AjG_7z9vouT73Abh9FMLsWAY4-h76HNbgsBUsIW8g4g4Bx707rsgrPYhA5voYvefZsHY7ELeDTZQcgJ71y-wrNvYTJ7R3H70pUwfB1jgq54sMnYg0kZxwDFlV1ZZPPuHJvPxfAUPeqNT_Dsrh6jT-dvNmeX1fr9xduz1bpquVqKivaKWWGlMFLKWhBqWK0s5QIkV62gRFlRKyFNJxtpC9RZQWvesLZRDKzkx-j1wXtlvB4nN5jpRkfj9OVqrfd_pMwhTPAtLeyrAztO8csMKevBpRa8NwHinDRbckUbVrO99uU_6HWcp1AuKdSyoZILUv8d3k4xpQn6-w0o0ftsdclW_862sC_ujLMdoLsn_4RZgNMDsHMebv5v0qsPm4PyFyUJr-4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779163504</pqid></control><display><type>article</type><title>Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><creator>Buisson, Anthony ; Nachury, Maria ; Guilmoteau, Thomas ; Altwegg, Romain ; Treton, Xavier ; Fumery, Mathurin ; Serrero, Melanie ; Leclerc, Eloïse ; Caillo, Ludovic ; Pereira, Bruno ; Amiot, Aurélien ; Bouguen, Guillaume</creator><creatorcontrib>Buisson, Anthony ; Nachury, Maria ; Guilmoteau, Thomas ; Altwegg, Romain ; Treton, Xavier ; Fumery, Mathurin ; Serrero, Melanie ; Leclerc, Eloïse ; Caillo, Ludovic ; Pereira, Bruno ; Amiot, Aurélien ; Bouguen, Guillaume</creatorcontrib><description>Summary
Background
Data comparing tofacitinib and vedolizumab in ulcerative colitis (UC) are lacking.
Aims
To compare the effectiveness of tofacitinib and vedolizumab in patients with UC who had prior exposure to anti‐TNF therapy
Methods
In this multicentre study, we included consecutive patients with UC ≥18 years old with partial Mayo score >2 and prior anti‐TNF exposure, who started tofacitinib or vedolizumab between January 2019 and June 2021. Comparisons were performed using propensity score analyses (inverse probability of treatment weighting).
Results
Overall, 126 and 178 patients received tofacitinib and vedolizumab, respectively. Intensified induction (vedolizumab infusion at week 10 or tofacitinib 10 mg b.d until week 16) was performed in 28.5% and 41.5% of patients, respectively.
After propensity‐score analysis, corticosteroid‐free clinical remission (partial Mayo score ≤2) was achieved at week 16 in 45.1% and 40.2% of patients receiving tofacitinib and vedolizumab, respectively (aOR = 0.82 [0.35–1.91], p = 0.64). Endoscopic improvement (corticosteroid‐free clinical remission and endoscopic Mayo score ≤1) (aOR = 0.23[0.08–0.65], p = 0.0032) and histological healing (endoscopic improvement + Nancy histological index ≤1) (13.4% vs 3.2%, aOR = 0.21[0.05–0.91], p = 0.023) were higher at week 16 in patients treated with tofacitinib. No factor was predictive of tofacitinib effectiveness. At least one primary failure to a biologic (OR = 0.46[0.22–0.99], p = 0.049), partial Mayo score >6 (OR = 0.39[0.17–0.90], p = 0.029) and CRP level > 30 mg/L at baseline (OR = 0.08[0.01–0.85], p = 0.036) were associated with vedolizumab failure.
Conclusion
Tofacitinib and vedolizumab are effective in UC after failure of anti‐TNF agents. However, tofacitinib seems more effective, especially in severe disease and primary failure to biologics.
Graphical showing the comparison between tofacitinib and vedolizumab to achieve steroid‐free clinical remission, endoscopic improvement and histological healing at week 16 in patients with ulcerative colitis exposed to at least one anti‐TNF agent</description><identifier>ISSN: 0269-2813</identifier><identifier>ISSN: 0953-0673</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.17305</identifier><identifier>PMID: 36401585</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Antibodies, Monoclonal, Humanized - therapeutic use ; Colitis, Ulcerative - drug therapy ; Endoscopy ; Gastrointestinal Agents - therapeutic use ; Human health and pathology ; Humans ; Inflammatory bowel disease ; Life Sciences ; Patients ; Performance evaluation ; Remission ; Remission (Medicine) ; Remission Induction ; Steroids ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors - therapeutic use ; Ulcerative colitis</subject><ispartof>Alimentary Pharmacology & Therapeutics (Suppl), 2023-03, Vol.57 (6), p.676-688</ispartof><rights>2022 John Wiley & Sons Ltd.</rights><rights>Copyright © 2023 John Wiley & Sons Ltd.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3875-1f82b5b65a6664501a248b135e638c5108b54856ad696ba66db514392c982eb63</citedby><cites>FETCH-LOGICAL-c3875-1f82b5b65a6664501a248b135e638c5108b54856ad696ba66db514392c982eb63</cites><orcidid>0000-0002-6347-409X ; 0000-0003-4618-7942 ; 0000-0001-6676-1222 ; 0000-0002-2337-2902 ; 0000-0002-7444-5905</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.17305$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.17305$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,1432,27915,27916,45565,45566,46400,46824</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36401585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://u-picardie.hal.science/hal-03870253$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Buisson, Anthony</creatorcontrib><creatorcontrib>Nachury, Maria</creatorcontrib><creatorcontrib>Guilmoteau, Thomas</creatorcontrib><creatorcontrib>Altwegg, Romain</creatorcontrib><creatorcontrib>Treton, Xavier</creatorcontrib><creatorcontrib>Fumery, Mathurin</creatorcontrib><creatorcontrib>Serrero, Melanie</creatorcontrib><creatorcontrib>Leclerc, Eloïse</creatorcontrib><creatorcontrib>Caillo, Ludovic</creatorcontrib><creatorcontrib>Pereira, Bruno</creatorcontrib><creatorcontrib>Amiot, Aurélien</creatorcontrib><creatorcontrib>Bouguen, Guillaume</creatorcontrib><title>Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent</title><title>Alimentary Pharmacology & Therapeutics (Suppl)</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Data comparing tofacitinib and vedolizumab in ulcerative colitis (UC) are lacking.
Aims
To compare the effectiveness of tofacitinib and vedolizumab in patients with UC who had prior exposure to anti‐TNF therapy
Methods
In this multicentre study, we included consecutive patients with UC ≥18 years old with partial Mayo score >2 and prior anti‐TNF exposure, who started tofacitinib or vedolizumab between January 2019 and June 2021. Comparisons were performed using propensity score analyses (inverse probability of treatment weighting).
Results
Overall, 126 and 178 patients received tofacitinib and vedolizumab, respectively. Intensified induction (vedolizumab infusion at week 10 or tofacitinib 10 mg b.d until week 16) was performed in 28.5% and 41.5% of patients, respectively.
After propensity‐score analysis, corticosteroid‐free clinical remission (partial Mayo score ≤2) was achieved at week 16 in 45.1% and 40.2% of patients receiving tofacitinib and vedolizumab, respectively (aOR = 0.82 [0.35–1.91], p = 0.64). Endoscopic improvement (corticosteroid‐free clinical remission and endoscopic Mayo score ≤1) (aOR = 0.23[0.08–0.65], p = 0.0032) and histological healing (endoscopic improvement + Nancy histological index ≤1) (13.4% vs 3.2%, aOR = 0.21[0.05–0.91], p = 0.023) were higher at week 16 in patients treated with tofacitinib. No factor was predictive of tofacitinib effectiveness. At least one primary failure to a biologic (OR = 0.46[0.22–0.99], p = 0.049), partial Mayo score >6 (OR = 0.39[0.17–0.90], p = 0.029) and CRP level > 30 mg/L at baseline (OR = 0.08[0.01–0.85], p = 0.036) were associated with vedolizumab failure.
Conclusion
Tofacitinib and vedolizumab are effective in UC after failure of anti‐TNF agents. However, tofacitinib seems more effective, especially in severe disease and primary failure to biologics.
Graphical showing the comparison between tofacitinib and vedolizumab to achieve steroid‐free clinical remission, endoscopic improvement and histological healing at week 16 in patients with ulcerative colitis exposed to at least one anti‐TNF agent</description><subject>Adolescent</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Endoscopy</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Inflammatory bowel disease</subject><subject>Life Sciences</subject><subject>Patients</subject><subject>Performance evaluation</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Remission Induction</subject><subject>Steroids</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor Inhibitors - therapeutic use</subject><subject>Ulcerative colitis</subject><issn>0269-2813</issn><issn>0953-0673</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQhy0EokvhwAsgS1zgkNZ_Yq9zXFW0RVoBQsvZspMJdeXYIXZ2Kac-AldejyfBy5YiIeHLSNY338zoh9BzSk5oeadmzCd0yYl4gBaUS1ExwuVDtCBMNhVTlB-hJyldE0LkkrDH6IjLmlChxAL9-AjG_7z9vouT73Abh9FMLsWAY4-h76HNbgsBUsIW8g4g4Bx707rsgrPYhA5voYvefZsHY7ELeDTZQcgJ71y-wrNvYTJ7R3H70pUwfB1jgq54sMnYg0kZxwDFlV1ZZPPuHJvPxfAUPeqNT_Dsrh6jT-dvNmeX1fr9xduz1bpquVqKivaKWWGlMFLKWhBqWK0s5QIkV62gRFlRKyFNJxtpC9RZQWvesLZRDKzkx-j1wXtlvB4nN5jpRkfj9OVqrfd_pMwhTPAtLeyrAztO8csMKevBpRa8NwHinDRbckUbVrO99uU_6HWcp1AuKdSyoZILUv8d3k4xpQn6-w0o0ftsdclW_862sC_ujLMdoLsn_4RZgNMDsHMebv5v0qsPm4PyFyUJr-4</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Buisson, Anthony</creator><creator>Nachury, Maria</creator><creator>Guilmoteau, Thomas</creator><creator>Altwegg, Romain</creator><creator>Treton, Xavier</creator><creator>Fumery, Mathurin</creator><creator>Serrero, Melanie</creator><creator>Leclerc, Eloïse</creator><creator>Caillo, Ludovic</creator><creator>Pereira, Bruno</creator><creator>Amiot, Aurélien</creator><creator>Bouguen, Guillaume</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-6347-409X</orcidid><orcidid>https://orcid.org/0000-0003-4618-7942</orcidid><orcidid>https://orcid.org/0000-0001-6676-1222</orcidid><orcidid>https://orcid.org/0000-0002-2337-2902</orcidid><orcidid>https://orcid.org/0000-0002-7444-5905</orcidid></search><sort><creationdate>202303</creationdate><title>Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent</title><author>Buisson, Anthony ; Nachury, Maria ; Guilmoteau, Thomas ; Altwegg, Romain ; Treton, Xavier ; Fumery, Mathurin ; Serrero, Melanie ; Leclerc, Eloïse ; Caillo, Ludovic ; Pereira, Bruno ; Amiot, Aurélien ; Bouguen, Guillaume</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3875-1f82b5b65a6664501a248b135e638c5108b54856ad696ba66db514392c982eb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescent</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Endoscopy</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Inflammatory bowel disease</topic><topic>Life Sciences</topic><topic>Patients</topic><topic>Performance evaluation</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Remission Induction</topic><topic>Steroids</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor Inhibitors - therapeutic use</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buisson, Anthony</creatorcontrib><creatorcontrib>Nachury, Maria</creatorcontrib><creatorcontrib>Guilmoteau, Thomas</creatorcontrib><creatorcontrib>Altwegg, Romain</creatorcontrib><creatorcontrib>Treton, Xavier</creatorcontrib><creatorcontrib>Fumery, Mathurin</creatorcontrib><creatorcontrib>Serrero, Melanie</creatorcontrib><creatorcontrib>Leclerc, Eloïse</creatorcontrib><creatorcontrib>Caillo, Ludovic</creatorcontrib><creatorcontrib>Pereira, Bruno</creatorcontrib><creatorcontrib>Amiot, Aurélien</creatorcontrib><creatorcontrib>Bouguen, Guillaume</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Alimentary Pharmacology & Therapeutics (Suppl)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buisson, Anthony</au><au>Nachury, Maria</au><au>Guilmoteau, Thomas</au><au>Altwegg, Romain</au><au>Treton, Xavier</au><au>Fumery, Mathurin</au><au>Serrero, Melanie</au><au>Leclerc, Eloïse</au><au>Caillo, Ludovic</au><au>Pereira, Bruno</au><au>Amiot, Aurélien</au><au>Bouguen, Guillaume</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent</atitle><jtitle>Alimentary Pharmacology & Therapeutics (Suppl)</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2023-03</date><risdate>2023</risdate><volume>57</volume><issue>6</issue><spage>676</spage><epage>688</epage><pages>676-688</pages><issn>0269-2813</issn><issn>0953-0673</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Data comparing tofacitinib and vedolizumab in ulcerative colitis (UC) are lacking.
Aims
To compare the effectiveness of tofacitinib and vedolizumab in patients with UC who had prior exposure to anti‐TNF therapy
Methods
In this multicentre study, we included consecutive patients with UC ≥18 years old with partial Mayo score >2 and prior anti‐TNF exposure, who started tofacitinib or vedolizumab between January 2019 and June 2021. Comparisons were performed using propensity score analyses (inverse probability of treatment weighting).
Results
Overall, 126 and 178 patients received tofacitinib and vedolizumab, respectively. Intensified induction (vedolizumab infusion at week 10 or tofacitinib 10 mg b.d until week 16) was performed in 28.5% and 41.5% of patients, respectively.
After propensity‐score analysis, corticosteroid‐free clinical remission (partial Mayo score ≤2) was achieved at week 16 in 45.1% and 40.2% of patients receiving tofacitinib and vedolizumab, respectively (aOR = 0.82 [0.35–1.91], p = 0.64). Endoscopic improvement (corticosteroid‐free clinical remission and endoscopic Mayo score ≤1) (aOR = 0.23[0.08–0.65], p = 0.0032) and histological healing (endoscopic improvement + Nancy histological index ≤1) (13.4% vs 3.2%, aOR = 0.21[0.05–0.91], p = 0.023) were higher at week 16 in patients treated with tofacitinib. No factor was predictive of tofacitinib effectiveness. At least one primary failure to a biologic (OR = 0.46[0.22–0.99], p = 0.049), partial Mayo score >6 (OR = 0.39[0.17–0.90], p = 0.029) and CRP level > 30 mg/L at baseline (OR = 0.08[0.01–0.85], p = 0.036) were associated with vedolizumab failure.
Conclusion
Tofacitinib and vedolizumab are effective in UC after failure of anti‐TNF agents. However, tofacitinib seems more effective, especially in severe disease and primary failure to biologics.
Graphical showing the comparison between tofacitinib and vedolizumab to achieve steroid‐free clinical remission, endoscopic improvement and histological healing at week 16 in patients with ulcerative colitis exposed to at least one anti‐TNF agent</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36401585</pmid><doi>10.1111/apt.17305</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-6347-409X</orcidid><orcidid>https://orcid.org/0000-0003-4618-7942</orcidid><orcidid>https://orcid.org/0000-0001-6676-1222</orcidid><orcidid>https://orcid.org/0000-0002-2337-2902</orcidid><orcidid>https://orcid.org/0000-0002-7444-5905</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary Pharmacology & Therapeutics (Suppl), 2023-03, Vol.57 (6), p.676-688 |
| issn | 0269-2813 0953-0673 1365-2036 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03870253v1 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content |
| subjects | Adolescent Antibodies, Monoclonal, Humanized - therapeutic use Colitis, Ulcerative - drug therapy Endoscopy Gastrointestinal Agents - therapeutic use Human health and pathology Humans Inflammatory bowel disease Life Sciences Patients Performance evaluation Remission Remission (Medicine) Remission Induction Steroids Treatment Outcome Tumor Necrosis Factor Inhibitors - therapeutic use Ulcerative colitis |
| title | Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T06%3A01%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90world%20comparison%20of%20effectiveness%20between%20tofacitinib%20and%20vedolizumab%20in%20patients%20with%20ulcerative%20colitis%20exposed%20to%20at%20least%20one%20anti%E2%80%90TNF%20agent&rft.jtitle=Alimentary%20Pharmacology%20&%20Therapeutics%20(Suppl)&rft.au=Buisson,%20Anthony&rft.date=2023-03&rft.volume=57&rft.issue=6&rft.spage=676&rft.epage=688&rft.pages=676-688&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.17305&rft_dat=%3Cproquest_hal_p%3E2738192426%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2779163504&rft_id=info:pmid/36401585&rfr_iscdi=true |